http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Prothena Corp. (PRTA) Secures $60M Milestone from Roche for First Patient Dosing in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
-
Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
-
Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena to Report First Quarter 2021 Financial Results on May 11th
-
Prothena to Report First Quarter 2021 Financial Results on May 11th
-
Prothena Corp. (PRTA) Highlights Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
-
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
-
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
-
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
-
Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
-
Prothena Corp. (PRTA) Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
-
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
-
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
-
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
-
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
-
Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
-
Prothena Corp. (PRTA) Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
-
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
-
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
-
Prothena Corp. (PRTA) Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004
-
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
-
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
-
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
-
Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
-
Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
-
Prothena to Report Third Quarter 2020 Financial Results on November 4
-
Prothena to Report Third Quarter 2020 Financial Results on November 4
-
Pre-Open Stock Movers 10/21: (ASTC) (SNAP) (CALX) Higher; (GSX) (NAVI) (NFLX) Lower (more...)
-
After-Hours Stock Movers 10/20: (ASTC) (SNAP) (PRTA) Higher; (NAVI) (NFLX) (APTX) Lower (more...)
-
Roche and Prothena (PRTA) will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
-
Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
-
Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
-
Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
-
Prothena Corp. (PRTA) Reports Data from Phase 2 PASADENA Study of Prasinezumab Demonstrates Slowing Progression on Measures of Parkinson’s Disease
-
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
-
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
-
Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
